Celcuity Inc. (CELC): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the driving force behind innovative cancer therapies? Celcuity Inc. (CELC), a clinical-stage biotechnology company, might just be the answer, with a mission to extend the lives of cancer patients. With a current market capitalization of $349 million and a stock price of $9.23 as of April 11, 2025, Celcuity is focused on developing targeted therapies for various cancers.

But how exactly does Celcuity operate, and what makes it stand out in the competitive biotech landscape? Join us as we delve into Celcuity's history, ownership structure, core mission, operational mechanisms, and revenue generation strategies, providing a comprehensive overview of this intriguing company.

Celcuity Inc. (CELC) History

Celcuity Inc.'s Founding Timeline

Year established

Celcuity Inc. was established in 2011.

Original location

The company is headquartered in Minneapolis, Minnesota.

Founding team members

Details on the specific founding team members are not available in the provided context. However, it is known that Brian Sullivan has served as the CEO since the company's inception.

Initial capital/funding

Specific details regarding the initial capital or funding of Celcuity Inc. at its founding are not available in the provided context.

Celcuity Inc.'s Evolution Milestones

Celcuity Inc.'s Transformative Moments

• 2018 IPO: The IPO provided Celcuity with substantial capital to advance its clinical programs and expand its research and development efforts.
• Strategic Collaborations: Partnerships with cancer centers like Vince Lombardi Cancer Center have validated Celcuity's technology and opened doors for further clinical applications and studies.
• Advancements in Diagnostic Technology: Continued development and validation of the CELsignia platform have positioned Celcuity as a key player in personalized cancer diagnostics, driving its mission to improve treatment outcomes.

For insights into the company's financial stability, see Breaking Down Celcuity Inc. (CELC) Financial Health: Key Insights for Investors.

Celcuity Inc. (CELC) Ownership Structure

Celcuity Inc. exhibits a mixed ownership structure, featuring a combination of institutional, insider, and retail investors, which influences its corporate governance and strategic direction.

Celcuity's Current Status

Celcuity Inc. is a publicly traded company, listed on the Nasdaq Capital Market under the ticker symbol CELC. This status allows the company to raise capital through the issuance of stock and makes it subject to regulations and reporting requirements by the U.S. Securities and Exchange Commission (SEC).

Celcuity's Ownership Breakdown

Celcuity's ownership is distributed among various types of shareholders. The following table summarizes the ownership percentages held by major categories of shareholders based on the latest available data:

Celcuity's Leadership

Celcuity's direction is guided by a team of experienced leaders. Key figures include:

• Brian Sullivan: Serves as the Chief Executive Officer.
• Vicky Hahne: Holds the position of Chief Financial Officer.
• Dr. Ravi Shanker: Functions as the Chief Medical Officer.

These individuals, along with other members of the executive team and board of directors, play crucial roles in shaping Celcuity's strategic initiatives and overseeing its operations. You might also be interested in: Mission Statement, Vision, & Core Values of Celcuity Inc. (CELC).

Celcuity Inc. (CELC) Mission and Values

Celcuity Inc. focuses on improving the lives of cancer patients through innovative diagnostic and therapeutic solutions. The company's core values center around scientific excellence, patient-centricity, and collaborative innovation.

Celcuity Inc.'s Core Purpose

Official mission statement

Celcuity's mission is to translate discoveries into diagnostics that enable personalized medicine and new medicines to treat cancer patients.

• To improve outcomes for cancer patients by offering innovative diagnostic tests.
• To develop targeted therapies that address the specific needs of individual patients.
• To advance the field of precision medicine in oncology through cutting-edge research and development.

Vision statement

Celcuity envisions becoming a leader in the field of personalized medicine for cancer, transforming patient care through innovative diagnostics and targeted therapies.

• To be recognized as a trusted partner by oncologists and pharmaceutical companies.
• To drive the adoption of personalized medicine approaches in cancer treatment.
• To create significant value for shareholders through successful product development and commercialization.

Company slogan/tagline

While Celcuity doesn't have a formal, publicly advertised slogan, its activities and focus suggest an implicit tagline centered around 'Personalized Medicine for Cancer.'

• Focus on precision medicine underscores their commitment to tailoring treatments.
• Emphasis on diagnostics highlights their approach to individualizing cancer care.

To delve deeper into Celcuity's mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of Celcuity Inc. (CELC).

Celcuity Inc. (CELC) How It Works

Celcuity Inc. operates as a cellular analysis company, primarily focused on discovering new cancer targets and personalizing cancer treatment through its diagnostic platform. The company leverages its proprietary CELsignia multi-omic diagnostic platform to analyze live tumor cells, identifying the signaling pathways driving cancer growth and helping to predict patient response to specific therapies.

Celcuity's Product/Service Portfolio

Celcuity's Operational Framework

Celcuity's operational framework revolves around its core technology, the CELsignia platform. The company generates revenue through:

• Partnerships with pharmaceutical companies: Celcuity collaborates with these companies to utilize its platform in clinical trials, aiding in patient selection and drug development.
• Companion diagnostic development: Developing and commercializing diagnostic tests that are paired with specific cancer therapies.
• Licensing agreements: Granting rights to use its technology to other entities for research and diagnostic purposes.

The process involves receiving tumor samples, processing them through the CELsignia platform, and delivering detailed reports on cellular signaling activity to partners. This information helps in making more informed decisions during drug development and patient treatment.

Celcuity's Strategic Advantages

Celcuity's strategic advantages stem from its unique technology and strategic positioning within the oncology diagnostics market:

• Proprietary Technology: The CELsignia platform offers a unique approach to analyzing live tumor cells, providing insights beyond traditional genomic analysis.
• Strategic Partnerships: Collaborations with major pharmaceutical companies validate the technology and provide revenue streams.
• Personalized Medicine Focus: By identifying the specific signaling pathways driving an individual's cancer, Celcuity supports the growing trend toward personalized cancer treatment.
• Companion Diagnostic Potential: Development of companion diagnostics offers a clear path to commercialization and revenue generation, aligning with the increasing demand for targeted therapies.

For further insights into Celcuity Inc.'s financial standing, you might find this resource helpful: Breaking Down Celcuity Inc. (CELC) Financial Health: Key Insights for Investors

Celcuity Inc. (CELC) How It Makes Money

Celcuity Inc. operates as a cellular analysis company, focusing on discovering new cancer targets and developing companion diagnostics for targeted therapies. The company generates revenue primarily through research and development collaborations with pharmaceutical companies.

Celcuity Inc.'s Revenue Breakdown

As Celcuity's business model revolves around partnering with pharmaceutical companies for research and development, its revenue streams are concentrated in collaborative agreements and related services. It is important to note that financial data is based on the latest available information, which may not always provide a complete breakdown by specific revenue stream.

Celcuity Inc.'s Business Economics

Celcuity's business economics are driven by its ability to identify unique drug targets and develop diagnostic tests that can predict a patient's response to specific cancer treatments. Key aspects of its business model include:

• Proprietary Technology: Celcuity utilizes its CELSignia platform to analyze cell signaling, which helps in identifying cancer subtypes and potential drug targets.
• Partnerships: The company collaborates with pharmaceutical firms to co-develop therapies and diagnostics, sharing the costs and revenues associated with these projects.
• Precision Medicine Focus: By focusing on personalized medicine, Celcuity aims to improve treatment outcomes and reduce healthcare costs by ensuring patients receive the most effective therapies.

To gain more insights into the company's strategic objectives, you might find this resource helpful: Mission Statement, Vision, & Core Values of Celcuity Inc. (CELC).

Celcuity Inc.'s Financial Performance

Celcuity's financial performance can be assessed through several key metrics and considerations:

• Revenue Growth: Revenue is significantly dependent on the progression of its collaborative projects.
• Operating Expenses: A substantial portion of expenses is allocated to research and development, reflecting the company's commitment to innovation.
• Cash Position: Monitoring Celcuity's cash reserves is crucial, as biotech companies often rely on funding to sustain operations during the development phase. As of December 31, 2024, Celcuity had total assets of $27.5 million and cash and cash equivalents of $17.8 million.
• Net Loss: As is typical for many biotech firms in the development stage, Celcuity has historically reported net losses. For the year ended December 31, 2024, the net loss was approximately $13.3 million.

Celcuity Inc. (CELC) Market Position & Future Outlook

Celcuity Inc. is a cellular analysis company, focusing on improving outcomes for cancer patients through its diagnostic platform, which aids in personalized medicine approaches. The company's future hinges on the continued clinical validation and commercial adoption of its CELsignia multi-omic diagnostic platform.

Competitive Landscape

The competitive landscape for Celcuity includes diagnostic companies with advanced platforms and pharmaceutical companies developing targeted therapies. While precise, up-to-the-minute market share data is challenging to obtain, the following table provides an illustrative overview based on available information and industry analysis as of early 2025.

Opportunities & Challenges

Celcuity faces both opportunities and risks in the dynamic field of cancer diagnostics and personalized medicine.

Industry Position

Celcuity occupies a niche position within the diagnostics industry, characterized by its focus on functional cellular analysis. Key aspects of its standing include:

• Precision Medicine Focus: The company aligns with the growing trend toward personalized cancer treatment strategies.
• Technological Differentiation: CELsignia platform offers a unique approach by analyzing cellular signaling pathways.
• Strategic Collaborations: Forming partnerships with pharmaceutical companies to enhance market penetration and expand diagnostic applications.

To gain more insights into the company's core principles, you might find this resource helpful: Mission Statement, Vision, & Core Values of Celcuity Inc. (CELC).